Stockscreener 앱 받기
219.70
1.69%
-3.77
전일 마감가:
$223.47
열려 있는:
$223.43
하루 거래량:
856.36K
Relative Volume:
0.94
시가총액:
$10.81B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
27.43
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
-0.55%
1개월 성능:
+12.54%
6개월 성능:
+41.80%
1년 성능:
+32.51%
1일 변동 폭
$218.90
$227.50
1주일 범위
$213.46
$228.88
52주 변동 폭
$91.86
$228.88
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
219.70 | 11.00B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
618.72 | 234.69B | 43.74B | 6.58B | 6.11B | 17.31 |
|
DHR
Danaher Corp
|
235.99 | 169.45B | 24.27B | 3.50B | 5.02B | 4.8589 |
|
IDXX
Idexx Laboratories Inc
|
715.37 | 56.86B | 4.17B | 1.03B | 940.22M | 12.61 |
|
IQV
Iqvia Holdings Inc
|
237.68 | 41.09B | 15.90B | 1.28B | 2.21B | 7.2842 |
|
A
Agilent Technologies Inc
|
139.64 | 41.06B | 6.95B | 1.30B | 1.15B | 4.5696 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-11-17 | 업그레이드 | Argus | Hold → Buy |
| 2025-11-06 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-10-06 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-10-02 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-09-09 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Is Charles River Laboratories (CRL) Pricing Reflect Recent Gains And Drug Discovery Contract Momentum - Yahoo Finance
Aug Reactions: What is the next catalyst for Charles River Laboratories International IncJuly 2025 Pullbacks & Short-Term High Return Ideas - baoquankhu1.vn
Here's Why Charles River Laboratories (CRL) is a Great Momentum Stock to Buy - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Charles River Labs (CRL) and Butterfly Network (BFLY) - The Globe and Mail
Charles River Laboratories stock hits 52-week high at $222.78 By Investing.com - Investing.com Australia
CRL: Strategic divestitures, acquisitions, and biotech demand recovery drive a positive 2026 outlook - TradingView — Track All Markets
Charles River Labs, Boston Scientific announce acquisitions during JPM - The Business Journals
Charles River Laboratories International (NYSE:CRL) Reaches New 12-Month HighStill a Buy? - MarketBeat
Charles River Laboratories stock hits 52-week high at $222.78 - Investing.com
Evercore ISI Group Raises Price Target for Charles River (CRL) t - GuruFocus
Charles River (NYSE: CRL) details 2026 outlook and two acquisitions - Stock Titan
Charles River Laboratories appoints Birgit Girshick as CEO following James Foster's retirement - MSN
Charles River to buy Cambodia-based monkey supplier for $510 million - Reuters
Evercore ISI Adjusts PT on Charles River Laboratories International to $260 From $250, Maintains Outperform Rating - marketscreener.com
Charles River Labs to acquire K.F. Cambodia and PathoQuest SAS By Investing.com - Investing.com Nigeria
A Look At Charles River Laboratories (CRL) Valuation As CEO Succession Plan Takes Shape - simplywall.st
Charles River Laboratories to acquire PathoQuest SAS from SHS Capital By Investing.com - Investing.com Canada
Healthcare Specialist SHS Capital agreed to sell PathoQuest to strategic buyer Charles River Laboratories - TradingView — Track All Markets
Charles River Laboratories Provides Business Updates - PharmiWeb.com
Charles River (CRL) Advances with Strategic Acquisitions and Lea - GuruFocus
Charles River Labs to acquire K.F. Cambodia and PathoQuest SAS - Investing.com
Charles River Laboratories International, Inc. $CRL Position Lowered by Iridian Asset Management LLC CT - MarketBeat
Charles River Laboratories (CRL) Stock Analysis: Navigating the Potential in a Challenging Market - DirectorsTalk Interviews
Why Charles River (CRL) Is Up 9.1% After Naming Long‑Time Insider Birgit Girshick CEO - simplywall.st
Charles River Labs Announces CEO Succession and Leadership Changes - The Globe and Mail
Is Now An Opportune Moment To Examine Charles River Laboratories International, Inc. (NYSE:CRL)? - simplywall.st
Charles River Laboratories (CRL) Announces Leadership Transition - GuruFocus
Charles River Laboratories announces CEO transition, Girshick to succeed Foster - Investing.com Australia
Charles River Labs (CRL) plans CEO succession and new board role for Foster - Stock Titan
What Makes Charles River Laboratories (CRL) an Investment Bet? - MSN
A Look At Charles River Laboratories (CRL) Valuation After Planned CEO Transition And Governance Shift - Yahoo Finance
Why Charles River Laboratories International Inc. stock stays resilientJuly 2025 Rallies & Reliable Trade Execution Plans - ulpravda.ru
Precision Trading with Charles River Laboratories International Inc. (CRL) Risk Zones - Stock Traders Daily
How Charles River Laboratories International Inc. stock compares to growth peersJuly 2025 Final Week & Community Consensus Trade Signals - ulpravda.ru
Will Charles River Laboratories International Inc. stock gain from lower inflationNew Guidance & Daily Chart Pattern Signal Reports - ulpravda.ru
Charles River Labs CEO to retire after more than three decades - NBC Boston
Charles River Laboratories Names Birgit Girshick CEO - citybiz
Charles River CEO Jim Foster to retire in May 2026 after 50-year career - Investing.com India
Can Charles River Laboratories International Inc. stock reach $100 price target2025 Market Outlook & AI Driven Price Predictions - ulpravda.ru
Charles River Laboratories International, Inc. Announces Chief Executive Officer Changes - marketscreener.com
What catalysts could drive Charles River Laboratories International Inc. stock higherMarket Movement Recap & Expert Verified Stock Movement Alerts - ulpravda.ru
Charles River Labs CEO to retire in 2026 after 30+ years at the helm - The Business Journals
Why Charles River Laboratories International Inc. stock is favored by pension funds2025 Technical Patterns & Weekly High Return Forecasts - ulpravda.ru
Charles River CEO Jim Foster to retire in May 2026 after 50-year career By Investing.com - Investing.com South Africa
Charles River Laboratories International, Chair, President, CEO James Foster to Retire - MarketScreener
Charles River Laboratories announces planned retirement of James C. Foster - marketscreener.com
Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan - Yahoo Finance
TD Cowen cuts Charles River Labs stock target on revenue pressures - MSN
Portfolio Recap: Is Charles River Laboratories International Inc RV6 stock a top pick for value investorsMarket Risk Analysis & High Accuracy Trade Alerts - moha.gov.vn
Charles River Laboratories International, Inc. (CRL) Hit a 52 Week High, Can the Run Continue? - sharewise.com
What Makes Charles River (CRL) a New Buy Stock - Yahoo Finance
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
0.74%
자본화:
|
볼륨(24시간):